SUBTYPES OF TRANSIENT MONOCULAR BLINDNESS AND SUBSEQUENT RISK OF VASCULAR COMPLICATIONS

Citation
Rcjm. Donders et al., SUBTYPES OF TRANSIENT MONOCULAR BLINDNESS AND SUBSEQUENT RISK OF VASCULAR COMPLICATIONS, Cerebrovascular diseases, 6(4), 1996, pp. 241-247
Citations number
24
Categorie Soggetti
Cardiac & Cardiovascular System","Clinical Neurology","Peripheal Vascular Diseas
Journal title
ISSN journal
10159770
Volume
6
Issue
4
Year of publication
1996
Pages
241 - 247
Database
ISI
SICI code
1015-9770(1996)6:4<241:SOTMBA>2.0.ZU;2-9
Abstract
Background and Purpose: Little is known about different varieties of t ransient monocular blindness (TMB) in relation to the subsequent occur rence of vascular outcome events. Very few studies have addressed the prognostic value of the form of the attack in patients with TMB. To tr y and distinguish benign and hazardous symptoms of TMB, we studied the prognosis of different subtypes of TMB in terms of subsequent vascula r complications. Methods: We analysed the characteristics of transient monocular loss of vision, vascular risk factors, and vascular events during follow-up in patients with TMB, who were recorded in the Royal Victoria Infirmary, Newcastle, United Kingdom (n = 137) or were entere d into the Dutch TIA Trial (n = 185). The mean follow-up period was 5. 0 years. The attacks were categorized in different 'patterns'. These p atterns were related to the occurrence of (1) the combined event of va scular death, stroke or myocardial infarction and (2) cerebral infarct ion (fatal or non-fatal). Results: Patients with attacks of blurred vi sion had a more than twofold risk of vascular outcome events than pati ents with blackened vision, complete or in part [hazard ratio (HR) 2.3 ; 95% confidence limits (CL) 1.2-4.5]. Involvement of only a part of t he visual field of one eye during the attack (instead of complete loss of vision) carried a lower risk (HR 0.4; 95% CL 0.2-0.9). Conclusion: Our findings suggest a relation between different types of TMB and ou tcome, but this needs to be validated in a subsequent cohort.